Christopher Parrish

Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses

Karishma Rajani, Christopher Parrish, Timothy Kottke et al. · Molecular Therapy · 2015 · 182 citations · Full text

High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial

Gordon Cook, Cathy Williams, Julia Brown et al. · The Lancet Oncology · 2014 · 151 citations · Full text

Hematological Malignancy, Transplantation, Marrow Transplantation +10

The effect of salvage autologous stem-cell transplantation on overall survival in patients with relapsed multiple myeloma (final results from BSBMT/UKMF Myeloma X Relapse [Intensive]): a randomised, open-label, phase 3 trial

Gordon Cook, A. John Ashcroft, David A. Cairns et al. · The Lancet Haematology · 2016 · 147 citations

Hematological Malignancy, Transplantation, Marrow Transplantation +10

Tumour Cell Generation of Inducible Regulatory T-Cells in Multiple Myeloma Is Contact-Dependent and Antigen-Presenting Cell-Independent

Sylvia Feyler, Gina B. Scott, Christopher Parrish et al. · PLoS ONE · 2012 · 72 citations · Full text

Oncolytic reovirus enhances rituximab-mediated antibody-dependent cellular cytotoxicity against chronic lymphocytic leukaemia

Christopher Parrish, Gina B. Scott, G Migneco et al. · Leukemia · 2015 · 51 citations · Full text